Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Standard curve

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    581 result(s) found for: Standard curve. Displaying page 1 of 30.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-002778-30 Sponsor Protocol Number: CLAF237A2357 Start Date*: 2005-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaire...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-023426-20 Sponsor Protocol Number: AUGUST-2 Start Date*: 2011-04-08
    Sponsor Name:GWT-TUD GmbH
    Full Title: Low dose Urokinase therapy in patients with diabetic foot syndrome, critical limb ischemia as well as rest ischemia or missing of option revascularisation in comparison to the standard therapy - ra...
    Medical condition: Diabetic foot syndrome with critical limb ischemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002071-34 Sponsor Protocol Number: Samba-01 Start Date*: 2013-03-28
    Sponsor Name:Dance Pharmaceuticals, Inc.
    Full Title: Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects with Type 1 Diabetes
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004463-69 Sponsor Protocol Number: RadiRet Start Date*: 2012-12-11
    Sponsor Name:Charité – University Medicine Berlin
    Full Title: Investigation of Radiation Retinopathy (RadiRet Study) Subtitle: Influence of Lucentis® on radiation retinopathy after irradiation of choroidal melanoma
    Medical condition: Patients with retinopathy, due to irradiation in uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10064714 Radiation retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001111-36 Sponsor Protocol Number: CAN04CLIN001 Start Date*: 2018-01-25
    Sponsor Name:Cantargia AB
    Full Title: An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
    Medical condition: Solid malignant tumors, in the following two indications; Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC),
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) DK (Completed) NL (Completed) DE (Completed) AT (Completed) EE (Completed) ES (Ongoing) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005914-18 Sponsor Protocol Number: APIDR_L_00465 Start Date*: 2006-03-15
    Sponsor Name:Diabetes-Centre Quakenbrueck
    Full Title: Effect of Insulin Glulisin on postprandial plasma glucose levels in obese subjectts with type 2 diabetes after a standard meal in comparison to Insulin Lispro
    Medical condition: Obese subjects with type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001381-96 Sponsor Protocol Number: LG_T1_EGP Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel
    Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept...
    Medical condition: Diabetes Mellitus Type 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003404-19 Sponsor Protocol Number: Ribavirin01 Start Date*: 2007-04-24
    Sponsor Name:Nutrim
    Full Title: Ribavirin: its dosing regime.
    Medical condition: Chronic Hepatitis C virus infection.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000524-26 Sponsor Protocol Number: UMCU2014-VASC-CO-001 Start Date*: 2015-05-19
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with familial dysbe...
    Medical condition: Familial Dysbetalipoproteinemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000258-12 Sponsor Protocol Number: 230189 Start Date*: 2014-10-15
    Sponsor Name:Orthopedic Research in Aarhus
    Full Title: Pharmacokinetics of vancomycin in cancellous and cortical bone obtained by microdialysis
    Medical condition: Orthopedic infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10050155 Knee prosthesis insertion LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000780-27 Sponsor Protocol Number: SPRINK-01 Start Date*: 2011-04-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: A single-center, randomized, controlled, 2-period cross-over, open-labelled trial to evaluate the impact of different application volumes on pharmacokinetic and pharmacodynamic properties of insul...
    Medical condition: Diabetes mellitus type I
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002318-37 Sponsor Protocol Number: J2H-MC-IUAA Start Date*: 2019-12-19
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900027 in Patients with Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy
    Medical condition: Type I Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000102-36 Sponsor Protocol Number: Everopolm Start Date*: 2008-02-21
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy.
    Medical condition: kidney disease after pulmonary transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038474 Renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001094-15 Sponsor Protocol Number: CDBC1 Start Date*: 2006-09-04
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital)
    Full Title: Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing
    Medical condition: Conditions for which carboplatin is indicated for: 1. Advanced ovarian carcinoma of epithelial origin in: - first line therapy - second line therapy, after other treatments have failed. 2. Small ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003011-58 Sponsor Protocol Number: CACZ885M2301S2 Start Date*: 2012-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000123-12 Sponsor Protocol Number: 2020110469 Start Date*: 2021-06-22
    Sponsor Name:Odense University Hospital
    Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging.
    Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000205-77 Sponsor Protocol Number: KF5503-75 Start Date*: Information not available in EudraCT
    Sponsor Name:Grünenthal GmbH
    Full Title: Open-label investigation of the pharmacokinetic profile, safety, tolerability, and efficacy of multiple administrations of tapentadol oral solution used for treatment of acute pain in children aged...
    Medical condition: Moderate to severe acute pain
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10066714 Acute pain LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010190-20 Sponsor Protocol Number: 0908010 Start Date*: 2009-04-22
    Sponsor Name:CHU Saint-Etienne
    Full Title: DETECTION OF ACUTE RENAL FAILURE IN CRITICALLY ILL PATIENTS: A prospective evaluation of cystatin C diagnostic performance
    Medical condition: critically ill patients hospitalised in inetnsive care unit
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003595-13 Sponsor Protocol Number: 17CS079 Start Date*: 2019-10-01
    Sponsor Name:Research and Innovation, Nottingham University Hospital
    Full Title: Pilot dose conversion study of extended release tacrolimus, Envarsus from standard twice daily tacrolimus in paediatric renal transplant recipients.
    Medical condition: Kidney transplantation - prevention of rejection.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-004137-21 Sponsor Protocol Number: 78591.041.21 Start Date*: 2021-10-28
    Sponsor Name:University Medical Center Utrecht
    Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study
    Medical condition: respiratory syncytial virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:37:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA